JNJ Stock Today: Johnson & Johnson Q3 2026 Earnings Beat, Raised Guidance and Live Price Action

Johnson & Johnson (NYSE: JNJ) reported third-quarter 2026 results on Tuesday, October 13, 2026, beating Wall Street estimates and raising its full-year earnings outlook, according to Yahoo Finance. The stock moved higher in premarket trading as investors digested a jump in quarterly pharmaceutical sales offset by softer medical-device revenue tied to Middle East conflict disruptions, CNBC reported. As of the October 13, 2026 session, JNJ remains one of the most searched dividend stocks on U.S. exchanges, with the related query "jnj stock price today per share" spiking alongside the earnings release.

What did Johnson & Johnson report for Q3 2026?

Johnson & Johnson delivered an earnings beat and lifted its 2026 guidance, driven by double-digit growth in oncology and immunology drugs. According to Yahoo Finance, the company topped consensus estimates on both revenue and adjusted earnings per share for the quarter ended September 2026. Bloomberg reported that the guidance raise was anchored in a jump in quarterly drug sales, particularly in the innovative medicine segment.

Key Q3 2026 highlights, based on company filings and wire reports:

• Adjusted EPS beat consensus, with management raising the full-year 2026 adjusted EPS range.
• Pharmaceutical revenue growth outpaced the prior-year quarter, led by oncology and immunology franchises.
• Medical-device sales were pressured by Middle East conflict-related disruptions, per CNBC.
• Full-year 2026 revenue guidance was maintained or raised, signaling confidence in the back half of the year.

How is JNJ stock trading today, October 13, 2026?

JNJ stock traded higher in the October 13, 2026 premarket session following the earnings beat and guidance raise. The exact live price per share fluctuates throughout the session, and investors tracking "jnj stock price today" should check real-time quotes on Yahoo Finance or CNBC. The stock has been a defensive holding in 2026, with its dividend yield and low beta attracting income investors amid broader market volatility.

Context for the move: the broader market has been choppy in October 2026, with the Dow Jones Industrial Average and S&P 500 swinging on rate and geopolitical headlines. JNJ's earnings beat provides a rare fundamental catalyst in a macro-driven tape.

JNJ stock price, dividend and split: the key facts

Johnson & Johnson has not announced a stock split in 2026, and the company's dividend remains a core part of its investment thesis. JNJ is a Dividend King with more than 60 consecutive years of dividend increases, and its forward yield has hovered in the 2.8% to 3.2% range in 2026 depending on the share price. There is no JNJ stock split on the table as of October 13, 2026.

Why did JNJ raise its 2026 guidance?

JNJ raised its 2026 guidance because pharmaceutical sales, particularly in oncology and immunology, grew faster than management expected. Bloomberg reported that the guidance lift followed a jump in quarterly drug sales, giving the company room to raise its full-year adjusted EPS outlook. The medical-device segment was the offset, with Middle East conflict disrupting procedures and supply routes, per CNBC.

This is a classic JNJ pattern: the innovative medicine segment carries growth, while medtech provides stability but is exposed to geopolitical shocks. Investors should watch whether the medtech drag is transient or extends into Q4 2026.

What is the JNJ stock forecast for 2026 and 2030?

The JNJ stock forecast for 2026 skews modestly bullish after the Q3 beat and guidance raise, with most sell-side models projecting mid-single-digit total returns driven by earnings growth plus the dividend. For 2030, long-range forecasts hinge on pipeline execution in oncology, immunology and neuroscience, plus the durability of the medtech recovery.

Analyst consensus, as tracked by Yahoo Finance and Bloomberg, generally assigns JNJ a moderate buy or hold rating with a price target range that implies limited near-term upside but strong downside protection. The 2030 case is less about multiple expansion and more about compounding: dividend reinvestment plus mid-single-digit EPS growth.

What are the biggest risks to JNJ stock right now?

The biggest risks to JNJ stock in October 2026 are geopolitical disruption to medical-device sales, drug pricing pressure, and litigation overhang. CNBC specifically flagged Middle East conflict as a weight on medical-device sales this quarter. Additional risks include patent cliffs in select drug franchises, currency headwinds, and any adverse legal rulings.

On the positive side, the guidance raise signals that management sees enough pipeline and commercial momentum to absorb those shocks. For income investors, the dividend remains the anchor.

How should investors think about JNJ stock today?

Investors should think about JNJ stock today as a defensive core holding with a fresh fundamental catalyst, not a high-beta trade. The Q3 2026 beat and raised guidance, reported by Yahoo Finance, Bloomberg and CNBC, reinforce the case for JNJ as a dividend compounder. The medtech drag from Middle East conflict is a watch item, not a thesis-breaker, unless it persists into 2027.

For live levels, check the current JNJ stock price today per share on Yahoo Finance, and for dividend specifics, review the company's investor relations page. The stock split question is settled: no split in 2026.

"J&J Lifts Earnings Outlook After Jump in Quarterly Drug Sales." Bloomberg, October 13, 2026.

Frequently asked questions about JNJ stock

What is the JNJ stock price today?

The JNJ stock price today, October 13, 2026, is moving higher after the Q3 earnings beat and guidance raise. Check Yahoo Finance or CNBC for the live per-share quote, as prices change throughout the session.

Did JNJ beat earnings in Q3 2026?

Yes. Johnson & Johnson beat estimates and raised its 2026 guidance, according to Yahoo Finance and Bloomberg.

Did JNJ announce a stock split in 2026?

No. There is no JNJ stock split announced in 2026 as of October 13, 2026.

What is the JNJ stock dividend?

JNJ is a Dividend King with more than 60 consecutive years of dividend increases. The forward yield has ranged around 2.8% to 3.2% in 2026 depending on the share price.

Why were JNJ medical-device sales weak in Q3 2026?

CNBC reported that Middle East conflict weighed on medical-device sales during the quarter, disrupting procedures and supply routes.

What is the JNJ stock forecast for 2030?

The 2030 forecast depends on pipeline execution in oncology, immunology and neuroscience, plus medtech recovery. Most long-range models project compounding returns driven by earnings growth and dividends rather than multiple expansion.